Product Description: BQ-788 sodium salt is a potent and selective ETB receptor antagonist, inhibiting ET-1 binding to ETB receptors with an IC50 of 1.2 nM in human Girrardi heart cells[1].
Applications: COVID-19-immunoregulation
Formula: C34H50N5NaO7
Citations: BMC Cancer. 2018 Feb 6;18(1):154./Environ Sci Pollut Res Int. 2018 May;25(15):14713-14725./J Neuroimmune Pharmacol. 2024 Apr 13;19(1):13./PLoS Pathog. 2020 Oct 19;16(10):e1008947./Cells. 2021, 10(11), 3072./Environ Pollut. 2016 Feb;209:11-20./Environ Pollut. 2016 Nov;218:487-496. /J Exp Clin Cancer Res. 2025 Feb 21;44(1):64./Neurotherapeutics. 2021 Oct 18./Toxicol Sci. 2016 Jan;149(1):213-26.
References: [1]Okada M, et al. BQ-788, a selective endothelin ET(B) receptor antagonist. Cardiovasc Drug Rev. 2002 Winter;20(1):53-66./[2]Sargent CA, et al. Effect of endothelin antagonists with or without BQ 788 on ET-1 responses in pithed rats. J Cardiovasc Pharmacol. 1995;26 Suppl 3:S216-8./[3]Fattori V, et al. Differential regulation of oxidative stress and cytokine production by endothelin ETA and ETB receptors in superoxide anion-induced inflammation and pain in mice. J Drug Target. 2016 Oct 5:1-27
CAS Number: 156161-89-6
Molecular Weight: 663.78
Compound Purity: 99.33
Research Area: Cardiovascular Disease; Endocrinology; Cancer
Solubility: DMSO : 25 mg/mL (ultrasonic;warming;heat to 60°C)/H2O : 20 mg/mL (ultrasonic)
Target: Endothelin Receptor
English
Deutsch
